Balance Sheet

v3.20.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Current assets:    
Cash $ 1,970,843 $ 2,645,852
Accounts receivable, net 750
Grant receivable 186,668
Prepaid expenses 1,547,703 213,283
Total current assets 3,518,546 3,046,553
Property and equipment, net 141,211 148,300
Right to use assets 435,625 458,707
Other assets:    
Patents, net 13,445 13,736
Intellectual property, net 212,220 224,010
Deposits, long term 41,936 41,936
Total other assets 267,601 279,682
Total assets 4,362,983 3,933,242
Current liabilities:    
Accounts payable and accrued expenses, including related party payables of $468,628 and $391,209, respectively 2,453,280 2,027,380
Deferred revenue, short term 115,000 134,924
Deferred revenue-grant 893,050
Lease liability, short term 79,388 76,977
Notes payable 21,480 21,480
Notes payable, related parties 290,110 290,110
Total current liabilities 3,852,308 2,550,871
Long term liabilities:    
Royalty obligation, net of discount of $6,693,764 and $6,812,318, related parties 2,028,336 1,909,782
Lease liability, long term 407,217 428,162
Deferred revenue, long term 94,592 103,313
Total liabilities 6,382,453 4,992,128
Commitments and contingencies
Deficit:    
Common stock, $0.001 par value; 750,000,000 shares authorized, 5,357,209 and 5,326,852 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively 100,000 100,000
Common stock subscribed 60,229,003 60,111,429
Additional paid in capital (62,282,642) (61,216,080)
Accumulated deficit (1,926,666) (977,708)
Total deficit attributable to BioCorRx, Inc. (92,804) (81,178)
Non-controlling interest (2,019,470) (1,058,886)
Total deficit 4,362,983 3,933,242
Total liabilities and deficit 4,362,983 3,933,242
Series A Preferred Stock [Member]    
Deficit:    
Series A convertible preferred stock, no par value; 80,000 designated; 80,000 shares issued and outstanding as of March 31, 2020 and December 31, 2019 5,616 5,616
Series B Preferred Stock [Member]    
Deficit:    
Series A convertible preferred stock, no par value; 80,000 designated; 80,000 shares issued and outstanding as of March 31, 2020 and December 31, 2019 $ 5,357 $ 5,327

Source